Cargando…

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)

Long-acting (LA) HIV pre-exposure prophylaxis (PrEP) offers the potential to improve adherence by lowering the burden of daily or on-demand regimens of antiretroviral (ARV) drugs. This paper details the fabrication and in vitro performance of a subcutaneous and trocar-compatible implant for the LA d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Leah M., Krovi, Sai Archana, Li, Linying, Girouard, Natalie, Demkovich, Zach R., Myers, Daniel, Creelman, Ben, van der Straten, Ariane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680758/ https://www.ncbi.nlm.nih.gov/pubmed/31277461 http://dx.doi.org/10.3390/pharmaceutics11070315

Ejemplares similares

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
por: Li, Linying, et al.
Publicado: (2020)

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques
por: Gatto, G. J., et al.
Publicado: (2022)

Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting
por: Romano, Joseph W., et al.
Publicado: (2021)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP)
por: Li, Linying, et al.
Publicado: (2021)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020)

“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
por: Pasipanodya, Elizabeth C., et al.
Publicado: (2021)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

2087. Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
por: Elion, Rick A, et al.
Publicado: (2022)

PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP
por: O'Byrne, Patrick, et al.
Publicado: (2019)

1287. PrEP-Engaged or PrEP Curious?: A Characterization and Comparison of Initial PrEP Appointment Attenders vs. Nonattenders
por: Kahal, Deborah A, et al.
Publicado: (2019)

Predictors of PrEP awareness, PrEP discussion and interest in long‐acting injectable PrEP among Filipina transfeminine adults
por: Restar, Arjee Javellana, et al.
Publicado: (2023)

Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial
por: Celum, Connie L, et al.
Publicado: (2020)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
por: Liu, Qing-Min, et al.
Publicado: (2021)

Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP
por: van Dijk, Mart, et al.
Publicado: (2021)

Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
por: Mangenah, Collin, et al.
Publicado: (2021)

PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV
por: Hill, Kristi C, et al.
Publicado: (2022)

Complex PrEP: the factors requiring consultant-led review of PrEP users
por: Tittle, Victoria, et al.
Publicado: (2022)

“You can’t have a PrEP program without a PrEP Coordinator”: Implementation of a PrEP panel management intervention
por: Saberi, Parya, et al.
Publicado: (2020)

981. Extended Adherence and Persistence to HIV PrEP in a Multidisciplinary PrEP Clinic
por: Whelchel, Kristen, et al.
Publicado: (2020)

Preparing for long‐acting PrEP delivery: building on lessons from oral PrEP
por: Celum, Connie, et al.
Publicado: (2023)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

“Yes, I’m interested in taking PrEP!”: PrEP interest among women respondents to the European community-based survey “Flash! PrEP in Europe”
por: Delabre, Rosemary M., et al.
Publicado: (2021)

Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study
por: Amico, K. Rivet, et al.
Publicado: (2016)

52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
por: Yacout, Hiba, et al.
Publicado: (2021)

Understanding the Association between PrEP Stigma and PrEP Cascade Moderated by the Intensity of HIV Testing
por: Zhang, Chen, et al.
Publicado: (2022)

PrEP Acceptance among Eligible Patients Attending the Largest PrEP Clinic in Jackson, Mississippi
por: Hollcroft, Madison R., et al.
Publicado: (2023)

Assessing the Impact of a PrEP Aware Week Campaign on PrEP Prescription Fills in NYS
por: Tesoriero, James M., et al.
Publicado: (2022)

The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
por: Solomon, Marc M., et al.
Publicado: (2016)

Perceptions, motivations, and beliefs about HIV risk and pre-exposure prophylaxis (PrEP) among participants in a nurse-led PrEP service (PrEP-RN)
por: Orser, Lauren, et al.
Publicado: (2022)

PrEP: controversy, agency and ownership
por: Cairns, Gus P, et al.
Publicado: (2016)

Pathopolitics: Pathologies and Biopolitics of PrEP
por: Atuk, Tankut
Publicado: (2020)

Navigating the Intersection of PrEP and Medicaid
por: Seiler, Naomi, et al.
Publicado: (2022)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention
por: Cremin, Ide, et al.
Publicado: (2015)

Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda
por: Muwonge, Timothy R., et al.
Publicado: (2020)

1965. PrEP On the Go! Implementation Mobile PrEP, STI, and HIV Prevention Services in South Florida
por: Doblecki-Lewis, Susanne, et al.
Publicado: (2019)

Patterns of Pre-exposure Prophylaxis (PrEP) Use in a Population Accessing PrEP in Jackson, Mississippi
por: Chase, Erin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i56n9mtivetajcgvphj8gjvcn7